EWM
BMY.RT

Endurance Wealth Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Endurance Wealth Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,200
Closed -$1K – 693
2020
Q4 		$1K Sell
1,200
-100
-8% -$213 ﹤0.01% 616
2020
Q3 		$3K Buy
+1,300
New +$3.71K ﹤0.01% 560

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Endurance Wealth Management's BMY.RT Position: Q1 2021 in Review

Endurance Wealth Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 1,200 shares — an estimated $1K sold.

Endurance Wealth Management first reported a position in BMY.RT in Q3 2020 and held it in 2 quarters. The position peaked at $3K in Q3 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Endurance Wealth Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Endurance Wealth Management sold 1,200 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $1K.
  • Endurance Wealth Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q3 2020 and held it in 2 quarters.
  • Endurance Wealth Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $3K in Q3 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Endurance Wealth Management's 13F filing for Q1 2021, filed 5 May 2021.